InvestorsHub Logo
icon url

ATLnsider

08/31/22 11:33 PM

#510017 RE: pqr #510015

Thank you pqr. I would also say that if a neuro-surgeon, or a neuro-oncologist, or any other GBM clinician, treat their ndGBM and rGBM patients with DCVax-L, and those patients have a significant increase in overall survival (OS), and some of those patients experience long-tail survival, and some of those patients are effectively cured (5+ years of complete remission), I think they would consider that to be clinically significant.